ATP8B2 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-87057
Key Product Details
Species Reactivity
Validated:
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Concentration
0.5 mg/ml
Product Summary for ATP8B2 Antibody
Immunogen
The immunogen is a synthetic peptide directed towards the N-terminal region of human ATP8B2. Peptide sequence: MPEKWARAQAPPSWSRKKPSWGTEEERRARANDREYNEKFQYASNCIKTS The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Scientific Data Images for ATP8B2 Antibody
![Western Blot: ATP8B2 Antibody [NBP2-87057]](https://resources.bio-techne.com/images/products/ATP8B2-Antibody-Western-Blot-NBP2-87057-img0001.jpg "Western Blot: ATP8B2 Antibody [NBP2-87057]")
Western Blot: ATP8B2 Antibody [NBP2-87057]
Western Blot: ATP8B2 Antibody [NBP2-87057] - Host: Rabbit. Target Name: ATP8B2. Sample Tissue: Human Mesenchymoma Tumor lysates. Antibody Dilution: 1ug/mlApplications for ATP8B2 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: ATP8B2
Alternate Names
ATPase, class I, type 8B, member 2, ATPIDprobable phospholipid-transporting ATPase ID, DKFZp434M0219, EC 3.6.3, EC 3.6.3.1, KIAA1137ATPase class I type 8B member 2, phospholipid-transporting ATPase ID
Gene Symbol
ATP8B2
Additional ATP8B2 Products
Product Specific Notices for ATP8B2 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...